NEUROCRINE BIOSCIENCES INC NBIX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
5/9
Piotroski F — financial health
6.21
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $2.9B | $478.6M | — | $748.7M | $3.3B |
| 2024 | $2.4B | $341.3M | — | $557.2M | $2.6B |
| 2023 | $1.9B | $249.7M | — | $361.6M | $2.2B |
| 2022 | $1.5B | $154.5M | — | $322.9M | $1.7B |
| 2021 | $1.1B | $89.6M | — | $233.1M | $1.4B |
| 2020 | $1.0B | $407.3M | — | $217.6M | $1.1B |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| SHERWIN STEPHEN A | director | 2026-06-05 | Option exercise | 10,000 | $79.79 |
| SHERWIN STEPHEN A | director | 2026-06-05 | Sell | 7,883 | $163.81 |
| SHERWIN STEPHEN A | director | 2026-06-05 | Sell | 2,549 | $164.44 |
| SHERWIN STEPHEN A | director | 2026-06-05 | Sell | 6,896 | $165.79 |
| SHERWIN STEPHEN A | director | 2026-06-05 | Sell | 5,829 | $166.56 |
| SHERWIN STEPHEN A | director | 2026-06-05 | Sell | 1,843 | $167.31 |
| Onyia Jude | Chief Scientific Officer | 2026-06-05 | Gift | 2,441 | — |
| SHERWIN STEPHEN A | director | 2026-06-05 | Option exercise | 15,000 | $53.64 |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 6.21 (safe)
- Working capital / assets 0.384
- Retained earnings / assets 0.097
- EBIT / assets 0.134
- Equity / liabilities 2.36
Source: SEC EDGAR filings · CIK 0000914475 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.